Clinical trial · Observational
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
NCT06181656CI-TRIAL-00112101recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To learn how radiation treatment may affect your responses to vaccines against pneumonia.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemoradiation | — | UNRESOLVED | — |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Lymphopenia | — | UNRESOLVED | — |
| Pneumococcal Vaccine | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pneumonia vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1
- description
- 30 participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer. This group will be subdivided into Group 1A, which will comprise 15 participants treated with proton therapy, and Group 1B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
- interventionNames
- Biological: Pneumonia vaccine
- label
- Group 2
- description
- 30 participants currently receiving, planning to receive, or recently completed chemoradiation for hepatocellular carcinoma. This group will be subdivided into Group 2A, which will comprise 15 participants treated with proton therapy, and Group 2B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
- interventionNames
- Biological: Pneumonia vaccine
- label
- Group 3
- description
- 20 Healthy Volunteers.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Group 1A a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons. 2. Group 1B a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (IMRT) 3. Group 2A a. Patients currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable liver cancer. 4. Group 2B a. Patients currently receiving, planning to receive, or recently completed definitive IMRT for unresectable liver cancer. 5. Group 3 a. Healthy age- and gender- matched individuals 6. All Groups 1. Patients of all genders, races and nationalities will be solicited. 2. Age \>18 years 3. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy a. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Patients receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment. * Patients with psychiatric illness/social situations that would limit compliance with study requirements. * Individuals with previous pneumococcal vaccination in the last 5 years. * Individuals with severe allergy to any of the vaccine components
References
Publications (0)
Data not yet available
No reference posted for this study.